Clinical bottom line
Clonal hematopoiesis of indeterminate potential (CHIP) is increasingly recognized as a common age-related condition characterized by the presence of somatic mutations in hematopoietic cells without overt hematologic malignancy. Emerging evidence links CHIP to elevated risks of cardiovascular disease and hematologic transformation. Novel agents targeting CHIP-associated pathways are under early investigation, aiming to mitigate these risks by modulating clonal expansion or inflammatory sequelae. While no therapies are yet approved specifically for CHIP, recent advances in modeling and drug discovery provide a foundation for future clinical interventions. Clinicians should remain aware of CHIP’s implications for cardiovascular and hematologic risk stratification but recognize that therapeutic targeting remains investigational.
What the evidence shows
CHIP is defined by the presence of somatic mutations in genes commonly mutated in hematologic malignancies—such as DNMT3A, TET2, and ASXL1—detected in peripheral blood cells at variant allele frequencies typically ≥2%, without diagnostic criteria for a hematologic neoplasm (Definitions et al., 2020). The prevalence of CHIP increases with age and is found in approximately 10-20% of individuals over 70 years old (Shah et al., 2019). Importantly, CHIP is associated with a 1.5- to 2-fold increased risk of cardiovascular events, including myocardial infarction and stroke, independent of traditional risk factors (Schnell et al., 2026).
Recent preclinical work has utilized self-organizing cardiac organoids (SCO) to model CHIP-driven cardiovascular disease, enabling mechanistic insights and drug screening platforms (Modeling et al., 2025). These models suggest that mutant hematopoietic clones promote systemic inflammation and endothelial dysfunction, contributing to atherosclerosis. Consequently, novel agents targeting inflammatory pathways, clonal expansion, or epigenetic regulators are under exploration to reduce CHIP-associated morbidity.
Current therapeutic strategies remain experimental and include inhibitors of inflammatory cytokines, agents modulating epigenetic enzymes mutated in CHIP clones, and drugs targeting downstream cardiovascular sequelae (Shah et al., 2019). However, no randomized controlled trials have yet demonstrated clinical benefit in CHIP populations, and no agents have regulatory approval specifically for CHIP.
Caveats and uncertainty
CHIP remains a putative risk factor rather than a disease entity with established treatment guidelines. The natural history of CHIP varies, with many individuals never developing hematologic malignancy or cardiovascular events. The heterogeneity of mutations and clone sizes complicates risk stratification and therapeutic targeting (Definitions et al., 2020).
The causal mechanisms linking CHIP to cardiovascular disease are incompletely understood, and it is unclear whether targeting CHIP clones directly or modulating downstream inflammation will yield clinical benefit. Preclinical models such as SCO provide promising platforms but require validation in human studies (Modeling et al., 2025).
Furthermore, the potential risks of intervening in CHIP clones—such as off-target effects or promoting clonal evolution—are unknown. The absence of prospective clinical trials means that current therapeutic approaches should be considered hypothesis-generating and investigational.
How this may change practice
Recognition of CHIP as a contributor to cardiovascular and hematologic risk is likely to increase, prompting clinicians to consider CHIP status in comprehensive risk assessments for older adults. While routine screening for CHIP is not currently recommended outside research settings, awareness of its implications may influence monitoring strategies.
As novel agents targeting CHIP-associated pathways progress through preclinical and early clinical development, future practice may incorporate targeted therapies to reduce cardiovascular events or prevent hematologic progression in high-risk CHIP carriers. Integration of CHIP status with traditional risk factors could refine personalized preventive strategies.
Clinicians should stay informed about emerging clinical trials and evolving evidence to guide potential future interventions. Meanwhile, management should focus on optimizing conventional cardiovascular risk factors and hematologic surveillance in patients identified with CHIP.